Phanes Therapeutics’ PT217 receives Orphan Drug Designation for Neuroendocrine Carcinoma from the FDA

SAN DIEGO, Aug. 16, 2024 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to…